Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A

Show simple item record

dc.contributor.author Valentino, L. A. en_US
dc.contributor.author Recht, M. en_US
dc.contributor.author Dipaola, J. en_US
dc.contributor.author Shapiro, A. D. en_US
dc.contributor.author Pipe, Steven W. en_US
dc.contributor.author Ewing, N. en_US
dc.contributor.author Urgo, J. en_US
dc.contributor.author Bullock, T. en_US
dc.contributor.author Simmons, M. en_US
dc.contributor.author Deguzman, C. en_US
dc.date.accessioned 2010-06-01T20:13:00Z
dc.date.available 2010-06-01T20:13:00Z
dc.date.issued 2009-05 en_US
dc.identifier.citation VALENTINO, L. A.; RECHT, M.; DIPAOLA, J.; SHAPIRO, A. D.; PIPE, S. W.; EWING, N.; URGO, J.; BULLOCK, T.; SIMMONS, M.; DEGUZMAN, C. (2009). "Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A." Haemophilia 15(3): 718-726. <http://hdl.handle.net/2027.42/73338> en_US
dc.identifier.issn 1351-8216 en_US
dc.identifier.issn 1365-2516 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/73338
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19298383&dopt=citation en_US
dc.format.extent 169371 bytes
dc.format.extent 3109 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Blackwell Publishing Ltd en_US
dc.rights © 2009 Blackwell Publishing Ltd en_US
dc.subject.other Advate en_US
dc.subject.other Haemophilia A en_US
dc.subject.other Immune Tolerance Induction en_US
dc.subject.other Inhibitor en_US
dc.subject.other Third-generation Recombinant Factor VIII en_US
dc.title Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A en_US
dc.type Article en_US
dc.subject.hlbsecondlevel Oncology and Hematology en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum ¶ Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA en_US
dc.contributor.affiliationother * Departments of Pediatrics and Internal Medicine, Rush University Medical Center, Chicago, IL, USA en_US
dc.contributor.affiliationother † Hemophilia Center, Phoenix Children’s Hospital, Phoenix, AZ, USA en_US
dc.contributor.affiliationother † Department of Pediatrics, University of Iowa Children’s Hospital, Iowa City, IA, USA en_US
dc.contributor.affiliationother § Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA en_US
dc.contributor.affiliationother ** Division of Pediatrics, City of Hope National Medical Center, Duarte, CA, USA en_US
dc.identifier.pmid 19298383 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/73338/1/j.1365-2516.2008.01960.x.pdf
dc.identifier.doi 10.1111/j.1365-2516.2008.01960.x en_US
dc.identifier.source Haemophilia en_US
dc.identifier.citedreference Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia. World Federation of Hemophilia: September 2004: no. 34. en_US
dc.identifier.citedreference Brackmann HH, Wallny T. Immune tolerance: high-dose regimen In: Rodriguez-Merchan EC, Lee CA eds. “Inhibitors in Patients with Hemophilia”. Oxford, England: Blackwell Science, Ltd, 2002: 45 – 8. en_US
dc.identifier.citedreference Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558 – 63. en_US
dc.identifier.citedreference Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402 – 6. en_US
dc.identifier.citedreference Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739 – 45. en_US
dc.identifier.citedreference Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167 – 72. en_US
dc.identifier.citedreference Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263 – 5. en_US
dc.identifier.citedreference Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267 – 72. en_US
dc.identifier.citedreference Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648 – 54. en_US
dc.identifier.citedreference Koestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120. en_US
dc.identifier.citedreference Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46 – 51. en_US
dc.identifier.citedreference Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228 – 36. en_US
dc.identifier.citedreference Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422 – 7. en_US
dc.identifier.citedreference Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 ( Suppl 1 ): 118 – 23. en_US
dc.identifier.citedreference Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93. en_US
dc.identifier.citedreference Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179 – 88. en_US
dc.identifier.citedreference White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560. en_US
dc.identifier.citedreference Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8. en_US
dc.identifier.citedreference Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626 – 30. en_US
dc.identifier.citedreference Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255 – 9. en_US
dc.identifier.citedreference Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113 – 9. en_US
dc.identifier.citedreference Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547 – 54. en_US
dc.identifier.citedreference Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 ( Suppl 1 ): 25 – 7. en_US
dc.identifier.citedreference DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52 – 7. en_US
dc.identifier.citedreference Lenk H. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85: 45 – 7. en_US
dc.identifier.citedreference Baxter Healthcare Corporation. ADVATE: [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2006. en_US
dc.identifier.citedreference Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363 – 71. en_US
dc.identifier.citedreference DiMichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271 – 3. en_US
dc.identifier.citedreference Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65 – 8. en_US
dc.identifier.citedreference Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947 – 50. en_US
dc.identifier.citedreference DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280 – 7. en_US
dc.identifier.citedreference Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84: 145 – 6. en_US
dc.identifier.citedreference Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800 – 5. en_US
dc.identifier.citedreference Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428 – 35. en_US
dc.identifier.citedreference Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 82: 1493. en_US
dc.identifier.citedreference Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594 – 8. en_US
dc.identifier.citedreference IITI. International, Randomised, Controlled Trial of Immune-Tolerance Induction. Available at: http://www.itistudy.com (accessed 12 January 2007). en_US
dc.identifier.citedreference Kurth MAH, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50 – 5. en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)

Search Deep Blue

Advanced Search

Browse by

My Account


Available Now

MLibrary logo